European committee says Lilly Alzheimer's drug shouldn't get marketing approval

Pantagraph | Bloomington

Mar 28, 2025

A European regulatory committee has rejected Eli Lilly's U.S.-approved Alzheimer's disease treatment over potentially dangerous risks of brain bleeding and swelling. The European M…